The next decade will bring shifts in technology, care delivery, and reimbursement, reshaping how capital is deployed across health care. As AI, care delivery, and new payment models converge, how are investors adapting? Leaders across growth equity, private equity, and public markets discuss their priorities and investment strategies to best position themselves for the health care ecosystem of 2030.

The women’s health movement is expanding beyond reproductive care to encompass every stage of life from fertility and maternal health to menopause and chronic disease. By 2030, will health systems and policies truly reflect women’s needs? This panel explores emerging models, investments, and technologies reshaping women’s health and the systemic changes required to make equity a reality.

As the locus of health shifts from hospitals and clinics to homes, devices, communities and mobile apps, what does this mean for systems, policy and people? This panel brings together voices from across pre-eminent consumer health companies to examine how consumer health is being transformed: the rise of digital diagnostics, home monitoring, wellness marketplaces, real-time data and new models of engagement. We’ll address how to build frameworks that scale, maintain trust and drive equity as we prepare for 2030.

Breakthrough therapies are redefining what’s possible in medicine, but also raising difficult questions about what those advances should cost. As new FDA and CMS regulations reshape the pricing landscape, leaders across pharma and biopharma are confronting the ethical tension between rewarding innovation and ensuring equitable access. This panel brings together experts from industry, policy, and payers to examine how pricing decisions reflect not only economics but values. Together, we’ll explore what the next era of drug pricing means for patients, profits, and the principles guiding progress.

As technology reshapes the landscape of public health, this panel examines how artificial intelligence, digital platforms, and real-time data are enabling smarter, faster, and more equitable health interventions. Experts will discuss innovative ways tech is being used to predict health trends, leverage behavioral health insights, and target interventions to help communities thrive. Topics include AI-assisted disease surveillance/early detection, digital equity, predictive modeling for prevention, and the ethical use of health data to improve community well-being.

GLP-1–based therapies have transformed the treatment of obesity and metabolic disease—but they’re only the beginning. With unprecedented capital flowing into the space, stakeholders across pharma, academia, and venture are asking: what’s next? From dual- and triple-agonists to oral formulations, novel targets, and real-world data tools that personalize treatment, a new wave of metabolic innovation is emerging. This panel explores how scientific progress, patient access, and investor priorities will shape the next phase of obesity therapeutics. How can pharma sustain differentiation in a crowded market? What translational research holds the most promise? And how will tech and data redefine success in weight management?